Novartis shelves potential blockbuster pelacarsen as landmark study fails
Summary
Novartis has decided to discontinue the development of pelacarsen after a major clinical trial failed to meet expectations. The drug was previously considered a potential blockbuster treatment for cardiovascular health.
Source: Read the full story at Stock Market News
Disclaimer: This content is for informational and educational purposes only and is not financial, investment or trading advice. Tech & Money Press is not a registered investment adviser or broker-dealer. Trading stocks, options and crypto involves substantial risk, including the loss of your entire investment. Do your own research and consult a licensed professional before making any financial decision. The authors may hold positions in the securities mentioned. News summaries are written with AI assistance from the original publisher's report and may contain errors; always check the original source. Full disclaimer.